Abeona Therapeutics Inc.
NASDAQ:ABEOBiotechnology
Healthcare
$2.73 +1.06%
+$0.06 today
- Market cap
- $156.01M
- Beta
- 1.35
- P/E (TTM)
- 4.9
- EPS (TTM)
- $1.17
52W Low $4.00High $7.54
Volume 1.71M
Average 1.12M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$76.33M
FY 2025 · Annual
Investing Cash Flow
$105.03M
FY 2025 · Annual
Financing Cash Flow
$26.04M
FY 2025 · Annual
-75.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (84.94M) | (39.7M) | (54.19M) | (63.73M) | 71.18M |
| Depreciation & Amortization | 4.46M | 4.58M | 3.2M | 2.91M | 3.56M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.92M | 3.05M | 4.77M | 6.63M | 10.78M |
| Change in Working Capital | (18.26M) | (5.89M) | (1.79M) | (4.38M) | (5.39M) |
| Accounts Receivables | (3M) | 2.81M | (2.04M) | 792K | (5.06M) |
| Inventory | 0 | 0 | 0 | 0 | (5.49M) |
| Accounts Payables | (15.59M) | (9.11M) | 2.04M | (3.49M) | 6.54M |
| Other Working Capital | 324K | 404K | (3.83M) | (1.68M) | (1.37M) |
| Other Non-Cash Items | 24.15M | (5.52M) | 11M | 2.57M | (156.46M) |
| Operating Cash Flow | (65.67M) | (43.48M) | (37.01M) | (56.02M) | (76.33M) |
| Capital Expenditures | (4.15M) | (130K) | (331K) | (2.45M) | (7.98M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.16M) | (78.21M) | (51.64M) | (157.01M) | (206.63M) |
| Sales of Investments | 90.38M | 52.64M | 51.97M | 120.2M | 167.27M |
| Other Investing Activities | 0 | 1.73M | 204K | 18K | 152.37M |
| Investing Cash Flow | 66.06M | (23.96M) | 208K | (39.24M) | 105.03M |
| Debt Repayment | 0 | 0 | 0 | 20M | 0 |
| Common Stock Issued | 24.03M | 46.96M | 37.39M | 85.63M | 26.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 831K | (5K) | (332K) | (1.49M) | (37K) |
| Financing Cash Flow | 24.86M | 43.17M | 37.06M | 104.14M | 26.04M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.26M | (24.27M) | 256K | 8.88M | 54.74M |
| Free Cash Flow | (69.82M) | (43.61M) | (37.34M) | (58.46M) | (84.3M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$71.2M
+ D&A$3.6M
+ Stock-Based Comp$10.8M
+ Deferred Tax$0
- Working Capital-$5.4M
- Other Non-Cash-$156.5M
= Operating Cash Flow-$76.3M
- Capex-$8.0M
= Free Cash Flow-$84.3M
Analysis
FY2025 free cash flow is -$84.3M. FCF conversion is -118.4% of net income. Operating cash flow was -$76.3M, with capex of -$8.0M. The largest bridge item is Other Non-Cash at -$156.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 |
Does ABEO generate free cash flow?
Abeona Therapeutics Inc. (ABEO) generated -$84.30M of free cash flow in fiscal 2025.
How much operating cash flow does ABEO produce?
Operating cash flow was -$76.33M, before capital expenditures of $7.97M.
Continue the stock analysis
Jump to another research area for this company.